A Mouse for All Reasons  by unknown
Leading Edge
CommentaryA Mouse for All Reasons
The International Mouse Knockout Consortium1,2,*
1Communicating authors: Francis S. Collins, National Human Genome Research Institute, National Institutes of Health, USA; 
Janet Rossant, Hospital for Sick Children, University of Toronto, Canada; Wolfgang Wurst, GSF-National Research Center for 
Environment and Health, Technical University, Munich, Germany
2For a full list of International Mouse Knockout Consortium members, please see http://www.cell.com/cgi/content/full/128/1/9/DC1/.
*Correspondence: francisc@mail.nih.gov
DOI 10.1016/j.cell.2006.12.018
Three major mouse knockout programs are underway worldwide, working together to 
mutate all protein-encoding genes in the mouse using a combination of gene trapping 
and gene targeting in mouse embryonic stem (ES) cells. Although the current emphasis is 
on production of this valuable resource, there are significant efforts to facilitate program 
coordination, to enhance the availability of this resource, and to plan for future efforts in 
mouse genetics research.The rapid advances and scale up of 
projects in DNA sequencing during 
the past 15 years have produced 
complete genome sequences of 
dozens of species. The great chal-
lenge facing biologists today is to 
ascribe function to the thousands 
of genes discovered through these 
efforts. Answering this challenge 
requires description of the func-
tions of each gene in normal physi-
ology and development, as well as 
the contribution of mutant alleles 
to inherited diseases. One power-
ful approach to help decipher the 
functions of genes is the manipula-
tion of genes in intact animals. The 
ability to perform gene knockouts 
in the laboratory mouse via ES cells 
has been a particularly successful 
research tool for nearly two dec-
ades, using two major methodolo-
gies: gene trapping and gene tar-
geting (see Note for definitions).
A survey of the Mouse Genome 
Informatics database (MGI; http://
www.informatics.jax.org) and the 
International Gene Trap Consor-
tium (IGTC; http://www.genetrap.
org) reveals that nearly 4000 tar-
geted knockouts of genes have 
already been made in mice and that 
another 7000 unique genes have 
been trapped in ES cells. Given the 
overlap between these sets, about 
9000 mouse genes in total have been 
knocked out. In contrast to the gene-
trapping efforts, which have produced 
readily available ES cell libraries, the gene-targeting efforts have thus far 
been accomplished mostly as a cot-
tage industry with many investigators 
contributing one or a few knockout 
mice engineered using a wide variety 
of approaches, and fewer than 900 
knockouts are actually available from 
a repository.
Participants at a 2003 meeting at 
the Banbury Center of the Cold Spring 
Harbor Laboratory proposed that the 
systematic mutagenesis of all protein-
encoding genes in the mouse would 
provide a standardized resource that 
would save time and expense (Austin et 
al., 2004). At the same time, pan-Euro-
pean discussions sponsored by the 
European Commission (EC) endorsed 
similar goals (Auwerx et al., 2004). Ele-
ments that supported these proposals 
included the availability of a highly 
accurate mouse genome sequence 
indicating a tractable number of genes; 
the high degree of homology between 
the mouse and human genomes; the 
excellent track record of the mouse 
as a model for human diseases and 
traits; and the sophisticated genetic 
tools and resources available for the 
mouse. The first step of the proposals 
has now come to fruition, and major 
mouse knockout programs are under-
way worldwide. Here, we describe the 
status of these efforts, the production 
goals, the methods for generation of 
research reagents, the plan to achieve 
close coordination among the pro-
grams, and the future direction of this 
research.Cell 128Three International Consortia
The complexity and cost of such an 
undertaking required the deployment 
and coordination of resources on a 
global scale. Three funding agencies, 
the U.S. National Institutes of Health 
(NIH), the EC, and Genome Canada 
and its partners have responded by 
funding such programs (see Supple-
mental Data available with this article 
online). These programs will use gene 
targeting and trapping to complete 
a resource of mutated ES cells and 
mice that will be comprehensive and 
will establish and support distribution 
centers and web-based data dissem-
ination to deliver these resources to 
the biomedical community.
KOMP (KnockOut Mouse Project, 
http://www.knockoutmouse.org), 
funded by the NIH, encompasses 
a number of efforts that all aim to 
enhance the availability and utility of 
mouse knockout strains. The first effort 
involved the acquisition of 251 knockout 
strains, and extensive associated phe-
notype data, from Deltagen and Lexicon 
Genetics. These strains were chosen 
from a list of approximately 2000 com-
mercially derived gene knockouts by 
an NIH committee comprised of scien-
tists representing areas of human dis-
ease and all major fields of biology. The 
strains have been deposited, as cryop-
reserved embryos, at two repositories 
and the data are available from the MGI 
database (http://www.informatics.jax.
org/external/ko/). A second effort of 
KOMP aims to support the deposition , January 12, 2007 ©2007 Elsevier Inc. 
Figure 1. Different Approaches for Gene Targeting
(Top) Targeted trapping of conditional alleles as carried out by KOMP and EUCOMM. The diagram 
depicts a model gene before and after homologous recombination with the targeted-trapping 
system. The abbreviation SAβgeoPA refers to an SV-40 splice acceptor site (SA), a promoterless 
β-galactosidase reporter gene followed by a promoterless neomycin-resistance gene (βgeo), and 
a polyadenylation signal (PA). A promoter driven neo cassette will be used to target genes not 
expressed in mouse ES cells. In both cases, the resultant allele is predicted to be null due to a 
strong splice acceptor in the expression cassette. The combination of FRT and loxP sites allows 
further manipulation to either remove the reporter cassette (1a) to restore wild-type expression or 
to delete the critical exon (1b). The allele in (1a) can be used in conjunction with Cre transgenic 
mice to produce conditional knockouts (2). 
(Bottom) Allele deletion carried out by KOMP’s Regeneron. This diagram demonstrates that the 
deletion, driven by homologous recombination with a recombineered BAC construct, removes 
all coding sequences of the gene and inserts an expression cassette driven off the endogenous 
gene's promoter. The abbreviation βgalpgkneo refers to a promoterless β-galactosidase reporter 
gene (βgal) and a phosphoglycerate kinase promoter driving the neomycin-resistance gene cas-
sette, which includes a polyadenylation signal (pgkneo).of additional mouse knockout strains, 
produced by academic researchers, 
into repositories. Toward that end, the 
Mutant Mouse Regional Resource 
Centers (http://www.mmrrc.org) are 
supported to “repatriate” and archive 
320 mouse strains for broad distribu-
tion. A prioritized list was generated 
from the set of all published mouse 
knockouts, and the investigators that 
published the strains are currently 
being requested to deposit their mice. 
The centerpiece of the KOMP knockout 
effort, however, consists of two pro-
grams that aim to create 8500 targeted 
mutations in ES cells in genes that 
have not yet been knocked out. The 
first is a consortium comprising The 
Children’s Hospital Oakland Research 
Institute, the Wellcome Trust Sanger 
Institute, and the University of Califor-10 Cell 128, January 12, 2007 ©2007 Elsnia at Davis (“CSD”). The other group 
consists of investigators at Regeneron 
Pharmaceuticals. Both groups have 
established high-throughput pipelines 
to target genes in mouse ES cells. The 
CSD group will create “null-first con-
ditional-ready” alleles (Figure 1). It is 
clear, however, that not all genes will be 
suitable for this allele design. Currently, 
compact genes and genes composed 
of complex transcript variants will not 
be readily amenable to this approach 
due to DNA sequence requirements 
to engineer the loxP sites flanking a 
critical exon that upon removal would 
ensure a null mutation. The use of 
BacVectors (targeting vectors with on 
average over 100 kb of homology), as 
developed by Regeneron, provides an 
alternate approach that is not depend-
ent on gene structure, gene expres-evier Inc.sion in ES cells, or a single exon that 
is critical for function. Regeneron will 
create null mutant alleles by deleting 
all or most of the exons in given genes, 
preferably from the initiator ATG codon 
to the stop codon (Valenzuela et al., 
2003; Figure 1). Additionally, as part 
of a quality-control effort, about 500 
mutant mouse strains will be generated 
by KOMP and made available through 
repositories (Table 1).
EUCOMM (EUropean Conditional 
Mouse Mutagenesis Program, http://
www.eucomm.org), funded by the 
FP6 program of the EC, combines the 
expertise of 11 research institutions 
across Europe and is coordinated by 
the GSF–National Research Center 
for Environment and Health and the 
Wellcome Trust Sanger Institute. The 
goals of the EUCOMM project are to 
produce 12,000 conditional gene trap 
mutations and 8000 conditional tar-
geted mutations in mouse ES cells 
(Table 1). From these, EUCOMM will 
generate up to 320 mutant mouse 
strains for genes of biological and 
medical relevance, mainly for qual-
ity-control reasons but also to deter-
mine gene function in vivo. The gene 
trapping and targeting vectors are 
designed to allow the generation of a 
null mutation as well as a conditional 
mutation (Schnütgen et al., 2005, Fig-
ure 1). In support of these efforts, the 
EUCOMM consortium will also pro-
duce 20 ligand-inducible, Cre-recom-
binase-expressing transgenic mice 
that will be available to the research 
community as well.
NorCOMM (North American Con-
ditional Mouse Mutagenesis Project, 
http://norcomm.phenogenomics.
ca/index.htm) is a Canadian project, 
funded by Genome Canada and 
partners, whose mission is to con-
tribute to the generation of a mouse 
ES cell resource with character-
ized mutations in every gene in the 
genome. Three centers in Canada 
are contributors to this initiative—the 
University of Manitoba, the Univer-
sity of Toronto, and the University of 
British Columbia. The project’s goals 
include the generation of 10,000 
gene trap insertion clones in ES cells 
derived from the 129 mouse strain 
using conditional-ready gene trap 
Table 1. International Mouse Gene Knockout Programs
Type of Resource Type of Knockout 2006 2007 2008 2009 2010 Totals
KOMP
ES Cell Targeted Deletion 175 500 941 942 942 3500
Mouse Targeted Deletion 50 50 50 50 50 250
ES Cell Targeted Conditional 1000 1000 1000 1000 1000 5000
Mouse Targeted Conditional 50 50 50 50 50 250
EUCOMM
ES Cell Trapped Conditional 3000 6000 3000 12,000
ES Cell Targeted Conditional 1000 3000 4000 8000
Mouse Mixed 20 100 200 320
NorCOMM
ES Cell Trapped Conditional 1000 4000 3000 2000 10,000
ES Cell Targeted Conditional 100 400 750 750 2000
Mouse Mixed 25 25 25 25 100
Cumulative for All Programs
ES Cell Trapped (Conditional) 4000 14000 20000 22000 22,000a
ES Cell Targeted (Deletion) 175 675 1616 2558 3500 3500
ES Cell Targeted (Conditional) 2100 6500 12,250 14,000 15,000 15,000
Mouse Mixed 125 400 715 830 920 920
Production timelines and totals are shown here. This table shows a timeline of unique gene knockout materials produced by the 
three programs: KOMP, EUCOMM, NorCOMM. Duplication will be avoided wherever possible through cooperation of the three 
organizations. The KOMP-related data will be collected and disseminated through the Data Coordination Center (DCC) that is 
being established at the Jackson Laboratory. The KOMP ES cell collection will be available to the entire research community. It is 
envisioned that the investigators will order ES cells from repositories with the option of receiving cells or of having the repository 
generate mice for an additional fee. A competition for a repository for the KOMP materials is underway. EUCOMM data on gene 
targeting vectors, mutant ES cells, mutant mouse lines, Cre-recombinase expressing transgenic mouse lines, mutation identifica-
tion tool kits, and Standard Operating Procedures will be presented at the EUCOMM website (http://www.eucomm.org). Vectors 
and ES cells will be distributed by the German Resource Center for Genome Research (RZPD; http://www.rzpd.de). All transgenic 
mouse lines will be archived as frozen embryos and disseminated by the European Mouse Mutant Archive (EMMA; http://www.
emmanet.org). The NorCOMM ES cell resource will be integrated with the Canadian Mouse Mutant Repository (CMMR) in coop-
eration with FIMRe (http://www.fimre.org). At their discretion, on a case-by-case basis, KOMP, EUCOMM, and NorCOMM may 
require investigators to send mice generated from the ES cells to a repository for cryo-preservation. 
aThe above numbers reflect estimates of unique genes trapped by the respective programs, but it is anticipated that there will be 
a 30%–40% overlap, resulting in ~14,000 unique gene traps from the combined efforts. Cell 128, January 12, 2007 ©2007 Elsevier Inc. 11vectors, 2000 targeted conditional 
mutant ES cell lines, and a toolbox 
of vectors and associated molecular 
reagents under development by the 
Samuel Lunenfeld Research Institute, 
Mount Sinai Hospital, to enhance the 
re-engineering of mutant lines.
All three efforts rely on high-qual-
ity annotation of genomic sequence 
for the identification of genes to 
ablate, for the design of targeting 
constructs, and for the interpretation 
of gene-trapping results. Toward that 
end, both EUCOMM and KOMP are 
supporting vertebrate genome anno-
tation (VEGA; http://vega.sanger.
ac.uk/) that will be performed largely 
at the Sanger Institute.The resources generated by these 
programs will be available from 
three distribution centers: the Ger-
man Resource Center for Genome 
Research (RZPD; http://www.rzpd.de), 
the KOMP repository (to be announced 
later, not yet funded), and the Canadian 
Mouse Consortium (CMC; http://www.
mousecanada.ca/index.htm). Investi-
gators can find reagents at these sites 




Historically, the vast majority of 
mouse knockouts have been gen-
erated using ES cells derived from the 129 mouse strain. Unfortunately, 
the 129 mouse strain has not been 
widely used in other fields of experi-
mentation and poses particular 
problems in immunology, neuro-
science, and physiology. Although 
ES cells have been made from 
C57BL/6, DBA, and BALB/c mouse 
strains, they have not yet demon-
strated the robustness needed to 
make a large-scale gene knockout 
project feasible. A workshop held at 
the NIH in March 2005 recognized 
the expediency of using 129 mouse 
ES cells, but participants strongly 
endorsed the development and use 
of C57BL/6 ES cells. Thus, three 
groups (University of Pennsylvania; 
Samuel Lunenfeld Research Insti-
tute, Mount Sinai Hospital, Toronto; 
and Regeneron Pharmaceuticals) 
are moving forward to further 
characterize and develop robust 
C57BL/6 ES cells for high-through-
put targeting efforts and implemen-
tation into the KOMP program.
Converging Scientific Strategies
In contemplating the range of strate-
gies that might be used to generate 
mutants of a large number of mouse 
genes at high efficiency and low 
cost, much discussion has centered 
around which technical approaches 
to use—for example, gene targeting 
or trapping, null or conditional alle-
les, and whether to include reporter 
genes (e.g., β-galactosidase). Fur-
ther discussions that have taken 
into consideration the complexi-
ties of gene structure and expres-
sion have yielded a synthesis of 
approaches, while continuing evolu-
tion of genetic resources and high-
throughput technologies have also 
influenced these plans. For exam-
ple, one advantage of trapping is 
that only a single (or small number) 
of vectors needs to be constructed 
to trap thousands of genes (Skarnes 
et al., 2004). In contrast, with tar-
geting, a vector has to be made for 
each gene that is to be mutated. 
Now, however, end-sequenced BAC 
libraries and recombineering meth-
ods (Copeland et al., 2001; Zhang et 
al., 1998) with the implementation of 
robotics allow the rapid construc-
tion of hundreds of targeting vec-
tors (Valenzuela et al., 2003), which 
can in principle be used to knock 
out any gene in ES cells. Moreo-
ver, development and implementa-
tion of high-throughput screens for 
ES cells that are correctly targeted 
using such vectors has enabled the 
efficient utilization of large numbers 
of targeting vectors (Valenzuela et 
al., 2003). As a second example, 
the adoption of promoterless selec-
tion cassettes into targeting vectors 
has greatly improved the efficiency 
in targeting expressed genes (Frie-
del et al., 2005; Testa et al., 2004), 
decreasing the advantage of trap-
ping in large-scale efforts. On the 12 Cell 128, January 12, 2007 ©2007 Elsother hand, an advantage of target-
ing, that it allows the design of con-
ditional alleles, is no longer as com-
pelling because conditional gene 
traps are now being made (Schnüt-
gen et al., 2005). Finally, the use 
of long homology arms in the con-
structs used for recombination may 
obviate the need for DNA constructs 
from the same strain (isogenic) 
(Valenzuela et al., 2003), eliminat-
ing a disconnect between genome 
reagents, that is, the standard 
C57BL/6 BAC library that was used 
to sequence the mouse genome, 
and ES cells that are derived from 
129 or other mouse strains. Thus, 
a combination of methods allows 
various approaches to be used in 
the construction of universal alleles 
that can be re-engineered as nulls, 
hypomorphs, or conditional knock-
outs. The development of technolo-
gies, the recognition of medical 
need for experimental models, and 
the common interests of strained 
funding agencies have resulted in, 
from the perspective of the mouse 
genome, a grand conjunction in the 
field of genetics.
Prioritization
Given the scale of the mouse knock-
out project, it should be possible to 
rapidly provide a collection of gene 
knockouts of immediate interest. 
EUCOMM has already selected a 
list of high-priority genes that is 
available at http://www.eucomm.
org. For the KOMP, a working group 
will make recommendations to the 
NIH, based on community input 
(http://www.knockoutmouse.org) 
regarding prioritization of which 
genes to knockout. Presumably, not 
all genes will be nominated, so that 
after ordering of nominated genes 
the working group will complete rec-
ommendations for prioritization of 
the remaining genes based on com-
pletion of known pathways, gene 
families, disease-related genes, 
expression profiles, and complete-
ness of the gene annotation. KOMP, 
EUCOMM, and NorCOMM have 
agreed to share gene lists and data 
to help coordinate these interna-
tional efforts.evier Inc.Future Directions
The participants of the 2003 Ban-
bury Conference envisioned that the 
completion of the ES cell knockout 
resource for the entire mouse genome 
would provide a foundation of maxi-
mum utility to the research commu-
nity and serve as a springboard for 
developing additional high-through-
put cost-saving efforts in functional 
genomics. For example:
Proven constructs with the pres-
ence of loxP and FRT (Flp recom-
binase target) sites will afford the 
opportunity to use recombinases 
to exchange reporter genes or 
introduce expression cassettes 
with human genes (or any trans-
gene or siRNA) into the vectors 
or directly in the targeted ES cell 
lines. These reagents will help to 
facilitate the future re-engineering 
of allelic mutations as our knowl-
edge of particular gene functions 
and human disease alleles grows. 
The specific introduction of dis-
ease-related mutations should 
significantly enhance modeling of 
human diseases in mice.
While all the above-mentioned 
efforts have incorporated the highly 
versatile and broadly accepted lacZ 
reporter, there are many instances 
where redesign of the reporter 
cassette to provide live-cell imag-
ing, molecular tags, or other mark-
ers could be highly advantageous. 
Having the reagents available from 
the original targeting experiment 
will greatly facilitate this switch.
Reporter expression profiles 
should also provide valuable data 
to allow the selection of the next 
generation of Cre driver strains, 
which can be easily developed 
using the construct and targeted 
ES cell resources.
The BacVectors with their very 
long regions of homology will also 
enhance the rate of homologous 
recombination in ES cell lines from 
other mouse strains that, while 
less robust for these large-scale 
projects, are from mouse strains 
preferred in specific areas of 
research.
The ES cells themselves are a valu-






vitro. The redesign of vectors with 
a different selection cassette could 
allow the production of homozygous 
mutant ES cells that can be studied 
in cell-based assays, differentiated 
into multiple cell types, and used 
as recipients for human transgenes 
(or knockin of a humanized locus) 
for drug screening or toxicology 
without the potential background 
of the mouse gene product. In fact, 
entire pathways potentially can be 
engineered.
Homozygous ES cells can be used 
as the “null benchmark” for the 
development of other mutagenesis 
approaches, such as siRNA, to 
validate these approaches in vitro 
prior to their application in whole 
animals.
It is important to note that generating 
mice from an ES cell line, by blas-
tocyst injection and breeding, and 
subsequent phenotyping of such 
mice is significantly more expensive 
than the creation of the knockout 
ES cell line. Furthermore, many labs 
have specialized research interests, 
such that many phenotypes may 
be missed for lack of expertise or 
broad systematic experimentation. 
If an expanded program can be 
mounted in the future, the proposed 
areas for centralized phenotyping 
might include expression analysis 
of the reporter gene, stage of lethal-
ity, activity, appearance and general 
behavior of the mice, blood chemis-
try, skeletal structure, cardiovascu-
lar function, urinalysis, MRI, and his-
tology of major organs and tissues. 
The number of targeted genes that 
can be studied in these programs 
will depend critically on funding. It 
is envisioned that specialized sec-
ond and third tier phenotyping such 
•as behavioral studies, immunologi-
cal challenge, physiology, cardio-
vascular disease assessment, and 
cancer occurrence, to name a few, 
will require highly specialized assays 
and can only reasonably be per-
formed on a subset of genes. There-
fore, those assays that are of higher 
cost and that require a higher degree 
of specialization will most likely need 
to be investigator driven.
The development of the vectors, 
mutant ES cells, mice, and distribu-
tion networks for the efforts of KOMP, 
EUCOMM, and NorCOMM to produce 
a knockout mutation for every gene in 
the mouse genome will not only pro-
vide valuable research tools in the 
short-term, decrease overall cost to 
the research community, and reduce 
time in producing experimental data, 
but it will also provide a foundation 
for future research in a wide variety of 
areas for many years to come.
Note
Definition of gene trapping and gene targeting: 
Gene trapping relies on the random integration 
in the genome of a DNA construct carrying a 
splice acceptor sequence and selection mark-
er. This strategy exploits the fact that when 
constructs integrate into introns, they create 
fusion transcripts through the action of the 
vector’s splice acceptor and express the se-
lection marker. The resulting truncation/fusion 
often leads to a knockout or a severe hypo-
morphic allele of the endogenous gene. Gene 
trapping has the advantage of being relatively 
inexpensive and can be performed using one 
or a few vectors. A significant limitation of this 
strategy is that it is only effective for genes that 
are expressed in ES cells, and there is also 
bias toward larger genes. Gene targeting is a 
directed approach that uses homologous re-
combination to mutate an endogenous gene. 
Specifically, this method can be used to delete 
a gene, remove exons, and introduce point 
mutations either permanently or in a condition-
al fashion. Gene targeting requires the creation 
of a specific vector for each gene of interest 
but can be used for any gene, regardless of 
transcriptional activity or gene size.Cell 128, Supplemental Data
Supplemental Data include the names and 
affiliations of all members of the International 
Mouse Knockout Consortium and can be 
found with this article online at http://www.
cell.com/cgi/content/full/128/1/9/DC1/.
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